Fresh From Farm raises $2 million in pre-series A

Fresh From Farm, a B2B2C platform for consolidating fresh fruit demand, has raised $2 million in a pre-series A round, with participation from Inflection Point Ventures. Spearheading this investment, is Ashish Kacholia, an investor in the public markets.

Fresh From Farm, a B2B2C platform for consolidating fresh fruit demand, has raised $2 million in a pre-series A round, with participation from Inflection Point Ventures. Spearheading this investment, is Ashish Kacholia, an investor in the public markets.

Fresh From Farm takes charge of retailers’ operations, overseeing procurement, handling, sorting and distribution, enabling them to focus solely on driving sales.

A media statement said the allocated funds will be utilised for team expansion, tech enhancement and to introduce new product lines.

It said that Fresh From Farm uses a proprietary tech interface to predict and create a demand-supply equilibrium to minimise wastage of fresh produce. Fresh From Farm converts fruit vendors into mini-franchises and sources, grades and handles fruit for them allowing them to focus on only sales.

Delivery at 300-plus locationsQuoting Rohit Nagdewani, Founder of Fresh From Farm, the statement said: “Our vision of becoming India’s largest fresh fruits company aligns with our efforts to expand aggressively in New Delhi/ NCR. While currently delivering at over 300-plus locations every day, our key focus at wastage reduction and efficient demand consolidation have allowed for our retailer partners to earn an average of 29 per cent more than working through traditional channels. On the growth front, we are aiming to touch ₹100 crore ARR (annual recurring revenue) by the end of this calendar year.”

Vikram Ramasubramanian, Partner, Inflection Point Ventures, said: “The concept of buying fresh fruits sounds fresh and healthy, but the process, however, is not. Behind every purchase lies a chain of individuals — farmers, labourers and retailers — working tirelessly to bring these products to market. Fresh From Farm steps in as a transformative force, streamlining this process with its tech-enabled platform”.

Ashish Kacholia, Founder of Lucky Investments, said: “The Fresh From Farm team is solving a large problem for fresh fruits retailers by handling their sourcing logistics and helping their quality of life. Consolidation of demand in an otherwise fragmented and unorganised market is the key driver of the business. Rohit and his team’s deep expertise on the subject matter and their focus on unit economics allowed us to build conviction for the investment”.

The statement said that Fresh From Farm operates with an ARR of ₹40 crore. Supporting this revenue stream is a team of 50 professionals. Anchored by a facility spanning 20,000 sq ft in New Delhi, the company leverages technology to uphold quality standards and meet market demand effectively, it said.

Like (0)
Previous April 29, 2024 4:08 pm
Next May 3, 2024 2:15 pm

Related posts

  • EV start-up EMotorad ends FY24 with 370% growth in domestic market

    EMotorad, a leading domestic premium electric cycle brand, has experienced a remarkable growth rate of over 370 per cent in India during FY24, with its customer base now exceeding 100,000 globally.

    US stock news April 19, 2024
  • Changyang Technology: Plans to invest in a colorless and transparent polyimide film project with an annual output of 1 million square meters

    Changyang Technology announced that the company plans to invest 302.48 million yuan through its wholly-owned subsidiary Zhejiang Changyang to build a colorless and transparent polyimide film project with an annual output of 1 million square meters. This project produces colorless and transparent polyimide film (CPI film), which is mainly used in flexible display structural components such as screen covers.

    US stock news April 25, 2024
  • JNK India IPO oversubscribed over 28 times, receives strong investor interest

    The initial public offering of heating equipment maker JNK India Ltd was subscribed over 28 times.

    US stock news April 26, 2024
  • Hope to win! The stock price of ST Guoan (000839) rose to the limit that day, and the shareholder compensation case is being consolidated and processed

    Log in to the Sina Finance APP and search [Xinpi] to view more stockholders who have suffered damage to their evaluation ratings. They can go to the Sina shareholder rights protection platform to register for the company to protect their rights: http://wq.finance.sina.com.cn/ Follow @Sina Securities, follow Sina on WeChat You can find us on brokerage funds, Baidu search, Sina investor rights protection, Sina Finance client, and Sina Finance homepage! On the evening of April 24, 2024, CITIC Guoan Information Industry Co., Ltd. (hereinafter referred to as \”ST Guoan (rights protection)\” or the \”Company\”) issued the \”Announcement on Application for Cancellation of Other Risk Warnings\”. The announcement stated that the circumstances in which the company was subject to \”other risk warnings\” have all been eliminated, and there is no major uncertainty in the company\’s ability to continue operating. In addition, there are no circumstances in which the company should be \”implemented in other risk warnings.\” ST Guoan has applied to the Shenzhen Stock Exchange Cancel the \”other risk warning\” imposed on the company\’s stock trading. In the secondary market, the company\’s…

    US stock news April 25, 2024
  • Chengyi Pharmaceutical: Net profit will increase by 0.81% year-on-year in 2023, with plans to send 2 yuan per 10 pieces

    Chengyi Pharmaceutical (603811) disclosed its 2023 annual report on April 26. In 2023, the company achieved operating income of 672 million yuan, a year-on-year increase of 2.54%; net profit attributable to the parent company was 163 million yuan, a year-on-year increase of 0.81%; non-net profit after deducting 155 million yuan, a year-on-year increase of 10.6%; net cash flow generated from operating activities was 195 million yuan, a year-on-year increase of 17.38%; during the reporting period, Chengyi Pharmaceutical’s basic earnings per share was 0.5 yuan, and the weighted average return on net assets was 14.35%. The company\’s 2023 distribution plan is: It plans to distribute 2 yuan (tax included) to all shareholders for every 10 shares.

    US stock news April 25, 2024
  • Keep up with these ETFs in the first quarter and have a higher winning rate

    At the beginning of the year, when the fund disclosed the four-season report, the biggest change in the mysterious institution\’s increase in positions was to focus on the large and let go of the small, and increase the position as a bonus. At that time, we mainly compared and analyzed broad-based index funds such as 50ETF, CSI 300ETF, CSI 500ETF, and CSI 1000ETF. We also compared the dividend index funds that the market paid attention to and the US stock QDII and Nikkei QDII to see the latest trends among investors. Data from the Jian Jinxin Fund Evaluation Center shows that the share of representative broad-based funds such as the Shanghai Stock Exchange 50ETF and the Shanghai-Shenzhen 300ETF showed a growth trend in the fourth quarter of 2023, especially the increase in the share of the Shanghai-Shenzhen 300ETF. (This is also the increase in the share of a certain team in the first quarter. The product with the largest number of positions); the share changes of several representative CSI 500 ETFs increased and decreased in the fourth quarter and the third quarter, and the trend is not obvious; the three larger CSI 1000 ETFs all experienced a shrinkage in share; good and stable profit making This effect has made investors more and more aware of dividend index funds, and many dividend index funds have reported rapid performance and scale in the fourth quarter. The market trend this year has also confirmed our analysis in early January.

    US stock news April 25, 2024